Lexaria Announces Agreement to Evaluate DehydraTECH With Unnamed Pharmaceutical Company
Lexaria Bioscience has entered into an Agreement with an unnamed pharmaceutical company to assess its DehydraTECH platform using proprietary molecules.
Lexaria Bioscience Corp. (NASDAQ:LEXX) has entered into an Agreement with an unidentified pharmaceutical company to assess its patented DehydraTECH drug-delivery technology using one or more proprietary molecules supplied by the company.
Announced on November 4, 2026, the arrangement covers an initial evaluation programme. Lexaria said the new Agreement is separate from and unrelated to its two existing Material Transfer Agreements with other pharmaceutical companies.
Under the arrangement, the pharmaceutical company, identified by Lexaria as “PharmCo”, will provide one or more proprietary molecules. Lexaria will process those molecules using DehydraTECH and evaluate the resulting formulations.
Lexaria has not disclosed PharmCo’s identity or the specific provisions of the Agreement, following a request from the pharmaceutical company.
Lexaria said that a successful evaluation could lead the parties to consider a licensing agreement containing customary commercial terms, including economic provisions. No licensing agreement has been announced.
The company intends to issue an update after the contemplated initial study or studies are completed. That update is expected to address whether the parties have made decisions concerning technology licensing or other business matters.
Lexaria said Liberi Group introduced the companies. Liberi Group is a life sciences and biotechnology business development consultancy working with Lexaria on its DehydraTECH partnering strategy.
Lexaria describes DehydraTECH as an oral drug-delivery formulation and processing platform. The company says the technology has repeatedly shown the ability to increase bio-absorption, reduce side-effects and help some drugs cross the blood-brain barrier more effectively.
Lexaria operates a licensed in-house research laboratory and said its intellectual property portfolio includes 70 patents granted, along with additional patents pending worldwide.
Lexaria said statements concerning its research work, regulatory approvals and possible study outcomes are forward-looking and subject to risks and uncertainties. The company said there is no assurance that its plans, intentions or expectations will be achieved.
Risks identified by Lexaria include government regulation and regulatory approvals, scientific discovery, the patent application and approval process, potential adverse effects associated with testing or using products involving DehydraTECH, maintaining existing collaborations, and delays or cancellations affecting planned research and development.
Lexaria also stated that no statement in the announcement had been evaluated by the Food and Drug Administration. It said there is no assurance that any proposed uses, benefits or advantages of the patented and patent-pending technology will be realised.
Lexaria Bioscience Corp. announced that it had entered into an Agreement with an unnamed pharmaceutical company, referred to as PharmCo, to investigate Lexaria’s DehydraTECH technology with one or more proprietary PharmCo molecules. The announcement concerns an evaluation arrangement, not a completed licensing agreement.
The Agreement sets out the conditions under which PharmCo will supply one or more proprietary molecules to Lexaria for processing with its patented DehydraTECH technology and evaluation. At PharmCo’s request, Lexaria will not disclose the company’s identity or specific details of the Agreement.
No, Lexaria said the new Agreement is separate from and has no relationship with its two Material Transfer Agreements already in place with other pharmaceutical companies.
Lexaria said that, if the evaluation process is successful, the parties will potentially move towards a licensing agreement with traditional terms, including economics. The source does not state that a licensing agreement has been reached.
Lexaria Bioscience Corp. announced the Agreement on November 4, 2026.
Lexaria will process one or more proprietary PharmCo molecules with its patented DehydraTECH technology for evaluation. Lexaria said it will provide an update when the contemplated initial study or studies are completed, including whether business decisions have been made about technology licensing or other business.
Lexaria said it was introduced to PharmCo through Liberi Group, a global life sciences business development consultancy working with Lexaria on its DehydraTECH partnering strategy.
Lexaria describes itself as a global innovator in drug delivery platforms. Its DehydraTECH technology is a patented drug delivery formulation and processing platform designed for oral delivery, and the company says it has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects and deliver some drugs more effectively across the blood brain barrier.
Lexaria said it holds a robust intellectual property portfolio with 70 patents granted and additional patents pending worldwide. The company also operates a licensed in-house research laboratory.
Lexaria Bioscience Corp. identifies its shares as listed on NASDAQ under the ticker symbol LEXX.
Lexaria said the forward-looking statements concerning its research initiatives, regulatory approvals and potential research results involve risks and uncertainties, and that there can be no assurance that its plans, intentions or expectations will be achieved. The company also said that potential risks include government regulation and regulatory approvals, scientific discovery, the patent application and approval process, potential adverse effects from testing or using products involving DehydraTECH, maintaining existing collaborations, and delays or cancellations of planned research and development; it added that no statement had been evaluated by the Food and Drug Administration and that there is no assurance that any postulated uses, benefits or advantages of the technology will be realised.